Loading stock data…
$4.30-0.31 (-6.72%)
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
Rezolute, Inc. in the Healthcare sector is trading at $4.26 with a market capitalization of $370M. Wall Street consensus targets $9.80 (10 analysts), implying a +129.8% move over the next 12 months. The stock is currently 63% below its 52-week high of $11.46, remaining 12.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$17.37M↑ | -$24.22M↓ | -$19.82M↑ | -$25.85M↓ | -$20.02M |
| Net Income | -$16.17M↑ | -$22.77M↓ | -$18.15M↑ | -$24.39M↓ | -$18.91M |
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal an...